Zevra Therapeutics (ZVRA) 10-K 30 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 28, 2018	Jun. 30, 2017
Document Information [Line Items]
Entity Registrant Name	KEMPHARM, INC
Entity Central Index Key	1,434,647
Trading Symbol	kmph
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		15,104,848
Entity Public Float			$ 46,538,484
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 10,871	$ 16,762
Restricted cash	1,100	1,100
Marketable securities	31,358	51,003
Trade date receivables	2,005	5,003
Prepaid expenses and other current assets	1,662	489
Total current assets	46,996	74,357
Property and equipment, net	2,004	1,970
Long-term investments	3,250	8,200
Other long-term assets	206	360
Total assets	52,456	84,887
Liabilities and stockholders’ deficit
Accounts payable and accrued expenses	7,875	6,444
Current portion of convertible notes	3,333
Current portion of capital lease obligation	189	157
Other current liabilities	112	41
Total current liabilities	11,509	6,642
Convertible notes, less current portion, net	89,398	91,170
Derivative and warrant liability	7,709	4,618
Capital lease obligation, less current portion	562	657
Other long-term liabilities	794	496
Total liabilities	109,972	103,583
Commitments and contingencies (Note G)
Stockholders' deficit:
Common stock, $0.0001 par value, 250,000,000 shares authorized, 14,657,430 shares issued and outstanding as of December 31, 2017; 14,646,982 shares issued and outstanding as of December 31, 2016	1	1
Additional paid-in capital	107,209	102,643
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2017 or December 31, 2016	0	0
Accumulated deficit	(164,726)	(121,340)
Total stockholders' deficit	(57,516)	(18,696)
Total liabilities and stockholders' deficit	$ 52,456	$ 84,887

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	14,657,430	14,646,982
Common stock, shares outstanding (in shares)	14,657,430	14,646,982
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue
Operating expenses:
Research and development	5,536	6,293	4,650	4,114	7,963	4,287	4,988	3,234	20,593	20,472	13,931
General and administrative	2,614	3,319	3,574	3,266	2,873	3,104	4,287	3,736	12,773	14,000	8,883
Severance expense						3,010				3,010
Total operating expenses	8,150	9,612	8,224	7,380	10,836	10,401	9,275	6,970	33,366	37,482	22,814
Loss from operations	(8,150)	(9,612)	(8,224)	(7,380)	(10,836)	(10,401)	(9,275)	(6,970)	(33,366)	(37,482)	(22,814)
Other (expense) income:
Loss on extinguishment of debt								(4,740)		(4,740)
Interest expense related to amortization of debt issuance costs and discount	(390)	(391)	(390)	(390)	(391)	(390)	(393)	(442)	(1,561)	(1,616)	(1,909)
Interest expense on principal	(1,444)	(1,448)	(1,443)	(1,441)	(1,445)	(1,441)	(1,475)	(1,150)	(5,776)	(5,511)	(2,671)
Fair value adjustment related to derivative and warrant liability	(710)	1,312	3,523	(7,216)	2,723	(1,299)	20,763	10,278	(3,091)	32,465	(27,276)
Interest and other income, net	97	154	13	101	9	98	144	102	365	353	32
Total other (expense) income	(2,447)	(373)	1,703	(8,946)	896	(3,032)	19,039	4,048	(10,063)	20,951	(31,824)
Loss before income taxes	(10,597)	(9,985)	(6,521)	(16,326)	(9,940)	(13,433)	9,764	(2,922)	(43,429)	(16,531)	(54,638)
Income tax benefit (expense)	31	4	4	4	4	19	4	(12)	43	15	(26)
Net loss	$ (10,566)	$ (9,981)	$ (6,517)	$ (16,322)	$ (9,936)	$ (13,414)	$ 9,768	$ (2,934)	$ (43,386)	$ (16,516)	$ (54,664)
Net loss per share:
Basic and diluted (in dollars per share)									$ (2.96)	$ (1.13)	$ (7.42)
Weighted average number of shares of common stock outstanding:
Basic and diluted (in shares)									14,652,898	14,597,053	7,368,681

Statements of Changes in Redeem

Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Deficit - USD ($) $ in Thousands	Preferred Stock [Member]Series A Redeemable Convertible Preferred Stock [Member]	Preferred Stock [Member]Series B Redeemable Convertible Preferred Stock [Member]	Preferred Stock [Member]Series C Redeemable Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Redeemable Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D-1 Redeemable Convertible Preferred Stock [Member]	Preferred Stock [Member]Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2014	$ 3,343	$ 3,313	$ 11,892	$ 5,659		$ 24,207
Balance at Dec. 31, 2014								$ 1,652	$ (50,160)	$ (48,508)
Net loss									(54,664)	(54,664)
Stock-based compensation expense								2,369		2,369
Exercise of stock options and warrants								4,749		4,749
Issuance of Series D-1 preferred stock					$ 4,000	4,000
Issuance of common stock in connection with IPO, net of discounts and commissions							1	59,891		59,892
Conversion of 2013 warrants to equity classification								1,110		1,110
Conversion of preferred stock into common stock upon IPO	$ (3,343)	$ (3,313)	$ (11,892)	$ (5,659)	$ (4,000)	$ (28,207)		28,207		28,207
Offering expenses charged to equity								(3,276)		(3,276)
Balance at Dec. 31, 2015							1	94,702	(104,824)	(10,121)
Net loss									(16,516)	(16,516)
Stock-based compensation expense								6,600		6,600
Exercise of stock options and warrants								896		896
Balance at Dec. 31, 2016							1	102,643	(121,340)	(18,696)
Write-off of deferred offering costs								445		445
Net loss									(43,386)	(43,386)
Stock-based compensation expense								4,562		4,562
Exercise of stock options and warrants								4		4
Balance at Dec. 31, 2017							$ 1	$ 107,209	$ (164,726)	$ (57,516)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (43,386,000)	$ (16,516,000)	$ (54,664,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on extinguishment of debt		4,740,000
Write-off of deferred offering costs	60,000	445,000
Stock-based compensation expense	4,562,000	6,600,000	2,369,000
Non-cash interest expense	2,222,000	2,222,000	2,671,000
Amortization of debt issuance costs and debt discount	1,561,000	1,616,000	1,909,000
Depreciation and amortization expense	336,000	175,000	84,000
Fair value adjustment	3,091,000	(32,465,000)	27,276,000
Loss on sublease and disposal of fixed assets	104,000	91,000
Change in assets and liabilities:
Prepaid expenses and other assets	(926,000)	2,018,000	(1,228,000)
Accounts payable and accrued expenses	(801,000)	1,118,000	1,315,000
Other liabilities	77,000	184,000
Net cash used in operating activities	(33,100,000)	(29,772,000)	(20,268,000)
Cash flows from investing activities:
Purchases of property and equipment	(181,000)	(643,000)	(135,000)
Purchases of marketable securities and long-term investments	(27,378,000)	(89,849,000)	(19,002,000)
Maturities of marketable securities	54,971,000	44,645,000
Net cash provided by (used in) investing activities	27,412,000	(45,847,000)	(19,137,000)
Cash flows from financing activities:
Proceeds from issuance of debt, net of discounts and commissions		82,800,000
Repayment of term notes and related accrued interest		(18,621,000)
Payment of principal on convertible notes arising from capitalized interest		(1,931,000)
Payment of deferred offering costs	(50,000)	(164,000)	(315,000)
Payment of debt and stock issuance costs		(983,000)	(2,533,000)
Repayment of obligations under capital lease	(157,000)	(79,000)	(32,000)
Proceeds from exercise of common stock options and warrants	4,000	141,000	413,000
Proceeds from initial public offering, net of discounts and commissions			59,892,000
Net cash (used in) provided by financing activities	(203,000)	61,163,000	61,468,000
Net (decrease) increase in cash, cash equivalents and restricted cash	(5,891,000)	(14,456,000)	22,063,000
Cash, cash equivalents and restricted cash, beginning of year	17,862,000	32,318,000	10,255,000
Cash, cash equivalents and restricted cash, end of year	11,971,000	17,862,000	32,318,000
Supplemental cash flow information:
Cash paid for interest	5,717,000	3,289,000
Trade date receivables	2,005,000	5,003,000
Property and equipment financed under a lease agreement	284,000	867,000
Transfer of warrants to equity upon exercise		755,000	4,293,000
Property and equipment included in accounts payable and accrued expenses	3,000	281,000
Deferred offering costs included in accounts payable and accrued expenses		85,000	428,000
Conversion of preferred stock into common stock upon initial public offering			28,207,000
Unpaid offering costs charged to equity			3,276,000
Reclassification of 2013 warrants to equity			1,110,000
Series D-1 Redeemable Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series D-1 redeemable convertible preferred stock			4,000,000
Series D Redeemable Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from exercise of common stock options and warrants			$ 43,000

Note A - Description of Busines

Note A - Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	A. Description of Business and Basis of Presentation Organization KemPharm, Inc. (the “Company”) is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy ("LAT") platform technology. The Company utilizes its proprietary LAT platform technology to generate improved prodrug versions of U.S. Food and Drug Administration (the "FDA") approved drugs in the high need areas of attention deficit hyperactivity disorder ("ADHD"), pain and other central nervous system ("CNS") disorders. The Company was formed and incorporated in Iowa on October 30, 2006 May 30, 2014. Going Concern The financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has experienced recurring losses from operations, stockholders' deficit and negative operating cash flows due to its ongoing research and development of its product and product candidates. The Company also has an accumulated deficit as of December 31, 2017. Management believes these conditions raise substantial doubt about the Company’s ability to continue as a going concern within the twelve Management intends to finance operating costs over the next twelve 3 $150.0 3 $20,000,000 Initial Public Offering and Reverse Stock Split In April 2015, 1 7.5 250,000,000 10,000,000 $0.0001 Reclassifications Certain prior year amounts have been reclassified to conform with current year presentation. During the second 2017, 2016 18, Statement of Cash Flows (Topic 230 2016 18” 2016 18 $1.1 December 31, 2016, not 2016 18. no not December 31, 2015. Entry into ATM Agreement On October 3, 2016, may $50,000,000 3 October 17, 2016. 3 $20,000,000 Cowen may 415 1933, may three 3.0% The Company is not December 31, 2017, $0.2 As of March 28, 2018, 446,111 $2.9

Note B - Summary of Significant

Note B - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	B. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, includ ing those related to the useful lives of property and equipment, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed insured limits. Cash and Cash Equivalents The Company considers any highly liquid investm ents with an original maturity of three Marketable Securities and Long-term Investments The Company maintains investment securities that are classified as trading securities. These securities are carried at fair value with unreali zed gains and losses included in other (expense) income on the statements of operations. The securities primarily consist of certificates of deposit, U.S. Treasury securities and U.S. government-sponsored agency securities. Property and Equipment The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three ten Debt Issuance Costs Debt issuance costs incurred in connection with financing arrangements are amortiz ed over the life of the respective financing arrangement using the effective interest method. Supply Arrangements The Company enters into supply arrangements for the supply of components of its product and product candidates. These arrangements also may share of future revenue if related product or product candidates reach commercialization. Costs under these supply arrangements, if any, are expensed as incurred (Note H). Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not No December 31, 2017, 2016 2015. Fair Value of Financial Instruments The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three equent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three ● Level 1 —Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2 —Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3 —Unobservable inputs that are supported by little or no Research and Development Major components of research and development costs include cash compensation, stock-based compensation, depreciation and amortization expense on research and development property and equipment, costs of preclinical studies, clin ical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Costs incurred in research and development are expensed as incurred. The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the statements of operations as the Company receives the related goods or services. The Company enters into contractual agreements with third pleted over an extended period of time. The Company records liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with the applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when the Company has not Patent Costs Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative expenses on the statements of operations. Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. Valuation allowances are recorded to reduce deferred tax assets to the amount the Company believes is more likely than not Uncertain tax positions are recognized only when the Company believes it is more likely than not t the tax position will be upheld on examination by the taxing authorities based on the merits of the position. The Company recognizes interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. The Company did not December 31, 2017 2016. The Company files income tax returns in the United States for federal and various state jurisdictions. With few exceptions, the Company is no 2013, 2013 may No Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers an d directors based on the estimated fair values of the awards as of the grant date. The Company records the value of the portion of the award that is ultimately expected to vest as expense over the requisite service period. The Company also accounts for equity instruments issued to non-employees using a fair value approach under Accounting Standards Codification ("ASC") subtopic 505 50. Basic and Diluted Net Loss per Share of Common Stock The Company uses the two entitle the holders to participate in dividends and earnings of the Company. The two Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is ava ilable and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company views its operations and manages its business as a single operating and reporting segment. All assets of the Company were held in the United States as of December 31, 2017 2016. Application of New or Revised Accounting Standards —Adopted From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date . On April 5, 2012, JOBS Act”) into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may not In November 2015, 2015 17, Income Taxes: Balance Sheet Classification of Deferred Taxes (Topic 740 2015 17” December 15, 2016, 2015 17 not In March 2016, 2016 06, Derivatives and Hedging (Topic 815 2016 06” 2016 06 December 15, 2016, 2016 06 not In March 2016, 2016 09, Compensation–Stock Compensation (Topic 718 2016 09” 2016 09 December 15, 2016, 2016 09 not In November 2016, 2016 18, applies to all entities that have restricted cash or restricted cash equivalents and are required to present a statement of cash flows. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2017, The Company early adopted ASU 2016 18 second 2017. 2016 18 Application of New or Revised Accounting Standards —Not In May 2014, 606, Revenue Recognition—Revenue from Contracts with Customers 606" 605, Revenue Recognition January 1, 2018. not not In January 2016, 2016 01, Financial Instruments Overall – Recognition and Measurement of Financial Assets and Liabilities (Topic 825 10 2016 01” 825 10. December 15, 2017, not 2016 01 In February 2016, 2016 02, Leases (Topic 842 2016 02” twelve 2016 02 December 15, 2018, 2016 02 . In August 2016, 2016 15, Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments (Topic 230 2016 15” eight 230. December 15, 2017, not currently expect ASU 2016 15 In May 2017, 2017 - 09, Compensation – Stock Compensation (Topic 718 ) – Scope of Modification Accounting ("ASU 2017 - 09" 718. This update applies to any entity that changes the terms or conditions of a stock-based payment award. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2017, not currently expect ASU 2017 - 09 to have a material effect on its financial statements and disclosures upon adoption. In July 2017, 2017 - 11, Earnings Per Share (Topic 260 ), Distinguishing Liabilities from Equity (Topic 480 ), Derivatives and Hedging (Topic 815 ) – I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception ("ASU 2017 - 11" 480 because of the existence of extensive pending content in the ASC as a result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. This update applies to all entities that issue financial instruments that include down round features and entities that present earnings per share in accordance with Topic 260. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2018, 2017 - 11 on its financial statements and disclosures.

Note C - Prepaid Expenses and O

Note C - Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Other Current Assets [Text Block]	C. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2017 2016 Prepaid insurance $ 202 $ 333 Other receivables 76 58 Other prepaid expenses and current assets 1,384 98 Total prepaid expenses and other current assets $ 1,662 $ 489

Note D - Property and Equipment

Note D - Property and Equipment	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	D. Property and Equipment Property and equipment consists of the following (in thousands): December 31, 2017 2016 Laboratory equipment $ 983 $ 842 Furniture and office equipment 655 733 Computers and hardware 292 231 Leasehold improvements 1,003 769 Total property and equipment 2,933 2,575 Less: accumulated depreciation and amortization (929 ) (605 ) Property and equipment, net $ 2,004 $ 1,970 The Company leases various equipment and leasehold improvements under capital lease agreements. The assets under capital leases are included in property and equipment as follows (in thousands): December 31, 2017 2016 Laboratory equipment $ 366 $ 271 Furniture and office equipment 541 537 Leasehold improvements 59 59 Total property and equipment financed under a capital lease agreement 966 867 Less: accumulated depreciation and amortization (150 ) (31 ) Property and equipment financed under a capital lease agreement, net $ 816 $ 836 The estimated useful lives of property and equipment are as follows: Useful Life Asset Category (in years) Laboratory equipment 10 Furniture and office equipment 5 - 10 Computers and hardware 3 - 7 Leasehold improvements 9 Depreciation and amortization expense, including amounts pertaining to assets held under capital leases, was approximately $336,000, $175,000 $84,000 December 31, 2017, 2016 2015,

Note E - Accounts Payable and A

Note E - Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	E. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following (in thousands): December 31, 2017 2016 Accrued interest $ 2,222 $ 2,222 Accrued banking fees 700 700 Accrued severance — 646 Accrued payroll 1,118 1,024 Accounts payable 2,177 469 Other accrued expenses 1,658 1,383 Total accounts payable and accrued expenses $ 7,875 $ 6,444

Note F - Debt Obligations

Note F - Debt Obligations	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	F. Debt Obligations Deerfield Facility Agreement On June 2, 2014, $60 first $15 $10 June 30, 2016, no 9.75% may $5.85 The Company also issued to Deerfield a warrant to purchase 14,423,076 Series D Preferred”) at an exercise price of $0.78 June 2, 2024 1,923,077 $5.85 260, Earnings per Share, may one third 12 1934, In addition, the Company issued to Deerfield 1,923,077 256, 410 $1.5 in the statements of operations. Pursuant to the Deerfield Fac ility Agreement, the Company may not $750,000 The Company must repay one third fourth fifth February 14, 2020. February 2016. Interest accrued on outstanding debt under the Deerfield Fa cility Agreement is due quarterly in arrears. Upon notice to Deerfield, the Company had the option to have one first eight July 1, 2016. eight June 30, 2016. July 1, 2016. Second Amendment to Senior Secured Convertible Note and Warrant On January 6, 2016, . Issuance of 5.50% Notes and Third Amendment to Senior Secured Convertible Note and Warrant On February 9, 2016, $86.3 5.50% 2021 2021 2021 144A The net proceeds from the Note Offering were approximately $82.8 ’ discount and estimated offering expenses. Concurrent with the Note Offering, the Company used approximately $18.6 The 2021 February 9, 2016 2021 February 1 August 1 August 1, 2016, 5.50% 2021 February 1, 2021 2021 not no 2021 The 2021 58.4454 ’s common stock per $1,000 2021 $17.11 2021 not 2021 If the Company undergoes a “ fundamental change” (as defined in the Indenture), holders may 2021 100% 2021 2021 one 2021 may The Indenture includes customary terms and covenants, including certain events of default after which the 2021 may In connection with the Note Offering, on February 3, 2016, 2021 Fourth Amendment to Deerfield Convertible Notes and Deerfield Warrant In connection with entering into the ATM Agreement, on October 3, 2016, 415 Convertible Notes Future minimum principal payments under convertible notes as of December 31, 2017, Convertible Year Ending December 31, Notes 2018 $ 3,333 2019 3,333 2020 3,334 2021 86,250 Total minimum principal payments 96,250 Less: debt issuance costs and discount (3,519 ) Convertible notes, net $ 92,731 Line of Credit During the second 2016, line of credit with a total borrowing capacity of $1.1 December 31, 2017 and 2016, $0.4 January 31, 2018. January 31, 2018, two January 31, 2020. December 31, 2017 and 2016, no no 1 2.00% 3.36%, December 31, 2017.

Note G - Commitments and Contin

Note G - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	G. Commitments and Contingencies Legal Matters From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is not not December 31, 2017 2016, no . In 2014, first ’s exclusive financial advisor for specified strategic transactions and to receive fees for the specified strategic transactions irrespective of whether any such specified transaction occurred during or after the term of the financial advisor’s service agreement. This filing by the former financial advisor was made in response to an action initiated by the Company in 2013 September 2015, not January 6, 2016, January 7, 2016. not In December 2016, registration statement in connection with its IPO, and each of the investment banks that acted as underwriters for the offering negligently issued untrue statements of material facts and omitted to state material facts required to be stated in the registration statement and incorporated offering materials that the Company filed with the SEC in support of the offering. The plaintiff does not In January 2017, January 2018, Cyan, Inc. v. Beaver County Employees Retirement Fund. March 20, 2018, Cyan one not Lease Agreements Iowa The Company leases office and laboratory facilities in Iowa under a non-can celable operating lease. The Company’s lease for its Iowa facilities expires in September 2018 one Florida The Company leases office space in Florida, comprised of two non-cancelable operating leases, which expire in August 2025 February 2026, two five Virginia The Company leases office and laboratory facilities in Virginia under a non-cancelable operating lease. The Company’s lease for its Virginia facilities expires in August 2018. North Carolina The Company leases office space in North Carolina under a non-cancelable operating lease. The expiration date of the Company ’s lease is May 2020, three second 2017, third third Capital Lease The Company leases various laboratory equipment, furniture and office equipment and leasehold improvements that are accounted for as capital leases and that require ongoing payments, including interest expense. The capital leases are financed through various financial institutions and are collateralized by the underlying assets. As of December 31, 2017 and 2016, 7.19% 8.05%. Rent expense for non-cancelable operating and capital leases was $0.6 million, $0.6 $0.3 December 31, 2017, 2016 2015, Future minimum lease payments under capital leases and non-cancelable operating leases as of December 31, 2017, Capital Operating Year Ending December 31, Leases Leases 2018 $ 242 $ 688 2019 231 604 2020 231 499 2021 151 449 2022 11 461 Thereafter — 1,376 Total minimum lease payments 866 $ 4,077 Less: amounts representing interest (115 ) Total minimum capital lease principal payments $ 751

Note H - Supply Arrangement

Note H - Supply Arrangement	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	H. Supply Arrangement As of December 31, 2017 and 2016, one potential future expenditures related to research and development. In November 2009, Supply Agreement”) with Johnson Matthey Inc. (“JMI”) whereby JMI has agreed to supply the Company with all of the KP201 KP201. KP201/IR, KP201. No December 31, 2017, 2016 2015. KP201 KP201 KP201 tenth KP201, two 12 not KP201. No

Note I - Preferred Stock and Wa

Note I - Preferred Stock and Warrants	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Preferred Stock [Text Block]	I. Preferred Stock and Warrants Authorized, Issued, and Outstanding Preferred Stock In April 2015, the number of its authorized shares of preferred stock to 10,000,000 $0.0001 April 2015, 5,980,564 December 31, 2017, 10,000,000 not Preferred Stock Activity The following table summarizes redeemable convertible preferred stock activity for the years ended December 31, 2017, 2016 2015: Shares of Series A Preferred Series B Preferred Series C Preferred Series D Preferred Series D-1 Preferred Total Balance as of January 1, 2015 9,704,215 6,220,000 18,557,408 7,255,425 — 41,737,048 Issuance of Series D-1 preferred stock — — — — 3,200,000 3,200,000 Exercise of Series D preferred warrants — — — 3,205 — 3,205 Effect of reverse stock split (8,410,377 ) (5,390,766 ) (16,083,286 ) (6,290,844 ) (2,784,416 ) (38,959,689 ) Less: Conversion of preferred stock into common stock upon IPO (1,293,838 ) (829,234 ) (2,474,122 ) (967,786 ) (415,584 ) (5,980,564 ) Balance as of December 31, 2015 — — — — — — Balance as of December 31, 2016 — — — — — — Balance as of December 31, 2017 — — — — — — Series D- 1 In February 2015, agreement with Cowen KP Investment LLC in which Cowen KP Investment LLC agreed to purchase and the Company agreed to sell 3,200,000 1 $1.25 $4.0 415,584 Warrants As described in Note A, in April 2015, Upon completion of the IPO, warrants to purchase 15,499,324 2,066,543 During 2013, $3.8 million of convertible notes and the warrants (the “2013 1,079,453 2013 2013 1,079,453 2013 143,466 $5.85 2013 June 2, 2019, On June 2, 2014, d Facility Agreement, the Company issued the Deerfield Warrant to purchase 14,423,076 June 2, 2024, 1,923,077 $5.85 The Company determined that the 2013 ty and stated at fair value at each reporting period upon inception. As stated above, upon completion of the IPO, the 2013 2013

Note J - Common Stock and Warra

Note J - Common Stock and Warrants	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	J. Common Stock and Warrants Authorized, Issued, and Outstanding Common Shares In April 2015, Incorporation to increase the number of its authorized shares of common stock to 250,000,000 14,657,430 14,646,982 December 31, 2017 2016, As of Dec ember 31, 2017 2016, December 31, 2017 2016 Conversion of Deerfield Convertible Notes 1,751,410 1,751,296 Conversion of 2021 Notes 5,040,914 5,040,914 Outstanding awards under equity incentive plans 2,853,924 1,990,260 Outstanding common stock warrants 2,027,763 2,087,477 Possible future issuances under equity incentive plans 944,700 1,244,671 Total common shares reserved for future issuance 12,618,711 12,114,618 Common Stock Activity The following table summarizes common stock activity for the years ended December 31, 2017, 2016 2015: Shares of Common Stock Balance as of January 1, 2015 2,381,041 Issuance of common stock in connection with the IPO 5,854,545 Conversion of preferred stock to common stock in connection with the IPO 5,980,564 Common stock warrants exercised 270,038 Common stock options exercised 4,766 Balance as of December 31, 2015 14,490,954 Common stock warrants exercised 141,095 Common stock options exercised 14,933 Balance as of December 31, 2016 14,646,982 Common stock warrants exercised 698 Common stock options exercised 9,750 Balance as of December 31, 2017 14,657,430 The Company calculates the fair value of common stock warrants using a Monte Carlo simulation. There were warrants exercised for an aggregate of 698, 141,095 270,038 December 31, 2017, 2016 2015, 2008 2012, 595,920 second second 2017. As of March 28, 2018, the Company has sold 446,111 $2.9

Note K - Stock-based Compensati

Note K - Stock-based Compensation	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	K. Stock-Based Compensation The Company maintains a stock-based compensation plan (the “ Incentive Stock Plan”) that governs stock awards made to employees and directors prior to completion of the IPO. In November 2014, April 2015, ’s stockholders, approved the Company’s 2014 “2014 April 2015. 2014 may 2014 3,432,183 December 31, 2017. 2014 January 1 January 1, 2016, January 1, 2024, 4% December 31 2014 January 1, 2018, 2014 586,297 During the years ended December 31, 2017, 2016 2015, 9,750, 14,933 4,766 $7,000, $71,000 $28,000 $32,000, $169,000 $54,000, Stock-based compensation expense recorded unde r the Incentive Stock Plan and the 2014 Year Ended December 31, 2017 2016 2015 Research and development $ 1,304 $ 1,051 $ 610 General and administrative 3,258 3,639 1,759 Severance expense — 1,910 — Total stock-based compensation expense $ 4,562 $ 6,600 $ 2,369 Stock Option Awards The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, which requires the use of subjective assumptions, including the expected term of the option, the expected stock price volatility, expe cted dividend yield and the risk-free interest rate for the expected term of the option. The expected term represents the period of time the stock options are expected to be outstanding. Due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected term of the stock options, the Company uses the simplified method to estimate the expected term for its “plain vanilla” stock options. Under the simplified method, the expected term of an option is presumed to be the mid-point between the vesting date and the end of the contractual term. Some options, for example those that have exercise prices in excess of the fair value of the underlying stock, are not ies and the Company over the estimated expected term of the stock options. The Company assumes no not not The Company recogni zes compensation expense related to stock-based payment transactions upon satisfaction of the requisite service or vesting requirements. Forfeitures are estimated at the time of grant and revised based on actual forfeitures, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Using the Black-Scholes option-pricing model, the weighted-average fair value of awards granted during the years ended December 31, 2017, 2016 2015, $2.77, $9.25 $10.63 re, respectively. The assumptions used to estimate fair value are as follows: December 31, 2017 2016 2015 Risk-free interest rate 1.88% - 2.26% 1.29% - 1.50% 1.40% - 1.99% Expected term (in years) 5.12 - 7.00 5.50 - 6.26 4.33 - 6.25 Expected volatility 85.35% - 95.08% 77.38% - 94.78% 68.79% - 86.84% Expected dividend yield 0% 0% 0% The activity under the Incentive Stock Plan and the 2014 for the year ended December 31, 2017, Weighted Average Number of Weighted Average Remaining Contractual Aggregate Intrinsic Options Exercise Price Term (in years) Value Outstanding balance as of January 1, 2017 1,990,260 $ 13.64 8.27 $ 26,400 Granted 919,000 $ 3.59 Exercised (9,750 ) $ 0.75 Canceled or forfeited (38,920 ) $ 11.35 Expired (6,666 ) $ 4.65 Outsta nding balance as of December 31, 2017 2,853,924 $ 10.50 7.90 $ 471,539 Exercisable as of December 31, 2017 1,044,392 $ 12.38 6.78 $ 29,237 Vested and expected to vest as of December 31, 2017 2,760,447 $ 10.62 7.87 $ 440,178 Information regarding currently outstanding and exercisable options as of December 31, 2017, Options Outstanding Options Exercisable Weighted Average Weighted Average Number of Remaining Contractual Number of Remaining Contractual Exercise Price Shares Term (in years) Shares Term (in years) $2.75 to $5.00 1,055,244 8.69 76,244 3.75 $5.01 to $10.00 366,447 5.77 345,146 5.72 $10.01 to $15.00 471,833 7.94 189,291 7.73 $15.01 to $20.00 612,600 7.89 259,811 7.76 $20.01 to $22.12 347,800 7.68 173,900 7.68 2,853,924 7.90 1,044,392 6.78 The total fair value of stock options vested during the years ended December 31, 2017, 2016 2015, $4.1 $5.4 $1.1 Unvested stock options as of December 31, 2017 2016, Number of Unvested Shares December 31, Exercise Price 2017 2016 $2.75 to $5.00 979,000 99,000 $5.01 to $10.00 21,301 97,480 $10.01 to $15.00 282,542 378,500 $15.01 to $20.00 352,789 516,938 $20.01 to $22.12 173,900 260,850 Total number of unvested shares 1,809,532 1,352,768 As of December 31, 2017, $8.5 ncentive Stock Plan and 2014 2.06 There was no December 31, 2017. December 31, 2016, $44,000 elated to performance-based awards included in research and development expenses. These awards were in connection with the strategic initiatives set for the award that were achieved in 2016 13,333 December 31, 2016. December 31, 2015, $0.7 elated to performance-based awards included in general and administrative expenses and $0.2 163,998 December 31, 2015.

Note L - Fair Value of Financia

Note L - Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	L. Fair Value of Financial Instruments The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash and accounts payable, approximate their respective fair values due to the short-term nature of such instruments. The fair value of the Deerfield Convertible Notes was $11.0 $10.2 December 31, 2017 2016. 2021 $51.9 $46.3 December 31, 2017 2016. 2021 3 2021 as of December 31, 2017 2016. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in whi ch to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2017 2016 Quoted Prices in Balance as of Active Markets for Significant Other Significant December 31, Identical Assets Observable Inputs Unobservable Inputs 2017 (Level 1) (Level 2) (Level 3) Deerfield Warrant liability $ 5,115 $ — $ — $ 5,115 Embedded Warrant Put Option 365 — — 365 Fundamental change and make-whole interest provisions embedded in 2021 Notes 14 — — 14 Embedded Deerfield Note Put Option 2,215 — — 2.215 Total liabilities $ 7,709 $ — $ — $ 7,709 Trading securities: Certificates of deposit 5,616 5,616 — — U.S. Treasury securities 25,988 25,988 — — U.S. government-sponsored agency securities 3,004 — 3,004 — Total assets $ 34,608 $ 31,604 $ 3,004 $ — Quoted Prices in Balance as of Active Markets for Significant Other Significant December 31, Identical Assets Observable Inputs Unobservable Inputs 2016 (Level 1) (Level 2) (Level 3) Underwriter Warrant liability $ 16 $ — $ — $ 16 Deerfield Warrant liability 4,231 — — 4,231 Embedded Warrant Put Option 365 — — 365 Fundamental change and make-whole interest provisions embedded in 2021 Notes 6 6 Total liabilities $ 4,618 $ — $ — $ 4,618 Trading securities: Certificates of deposit 7,788 7,788 — — U.S. Treasury securities 37,066 37,066 — — U.S. government-sponsored agency securities 14,349 — 14,349 — Total assets $ 59,203 $ 44,854 $ 14,349 $ — The Company ’s Underwriter Warrant liability, Deerfield Warrant liability, embedded Warrant Put Option, the fundamental change and the make-whole interest provisions embedded in the 2021 December 31, 2017 2016, 2021 December 31, 2017, 2021 December 31, 2017 2016. December 31, 2017. 2021 fair value adjustment. A reconciliation of the beginning and ending balances for the derivative and warrant liability measured at fair value on a recurring basis using signific ant unobservable inputs (Level 3 2017 2016 Balance as of beginning of period $ 4,618 $ 37,839 Exercise of warrants — (756 ) Adjustment to fair value 3,091 (32,465 ) Balance as of end of period $ 7,709 $ 4,618

Note M - Income Taxes

Note M - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	M. Income Taxes The Company ’s financial statements include a total state tax benefit related to research and development credits of $43,000, $15,000 $15,000 $43.4 $16.5 $54.6 December 31, 2017, 2016 2015, Year ended December 31, 2017 2016 2015 Federal statutory rate 34.00 % 34.00 % 34.00 % Effect of: Change in valuation allowance 13.38 (69.31 ) (19.25 ) Return to provision and deferred true-up 2.18 (23.83 ) — Change in rate (49.06 ) (14.63 ) — State tax benefit (net of federal) 2.71 15.64 4.06 Warrant liability (2.42 ) 68.44 (15.28 ) State research and development credit 0.10 0.09 0.03 Federal research and development credit 1.50 5.65 0.84 Amortization (1.22 ) (3.15 ) — Conversion feature and put option on convertible notes — — (1.68 ) Stock-based compensation (1.03 ) (12.71 ) (1.28 ) Other (0.04 ) (0.10 ) (1.49 ) Federal income tax benefit (provision) effective rate 0.10 % 0.09 % (0.05 )% The components of deferred tax assets and liabilities are as follows (in thousands): December 31, 2017 2016 2015 Deferred tax assets relating to: Net operating loss carryforwards $ 37,028 $ 44,984 $ 26,617 Research and development tax carryforward 3,788 3,166 2,254 Other deferred tax assets 2,409 715 232 Total gross deferred tax assets 43,225 48,865 29,103 Deferred tax liabilities relating to: Property and equipment 260 89 80 Total gross deferred tax liabilities 260 89 80 Deferred tax assets less liabilities 42,965 48,776 29,023 Valuation allowance (42,965 ) (48,776 ) (29,023 ) Net deferred tax asset (liability) $ — $ — $ — H.R. 1, 2018” "2017 December 22, 2017. 2017 35% 21%, one 2017 2026 Also on December 22, 2017, No. 118 118” 2017 118 not one 2017 740, December 31, 2017, not 2017 However, the Company has made reasonable estimates of the effects on its income tax provision with respect to certain items, primarily the revaluation of its existing U.S. deferred tax balances as described above. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not not assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not not The Company had the following federal net operating loss carryforward and research activities credits as of December 31, 2017 ( Net Operating Research Year Incurred Loss Carryforwards Activities Credit Expiration 2007 $ 454 $ 30 2027 2008 1,178 65 2028 2009 3,060 176 2029 2010 3,423 149 2030 2011 9,929 176 2031 2012 — 170 2032 2013 4,353 133 2033 2014 16,265 894 2034 2015 24,126 598 2035 2016 40,715 745 2036 2017 33,828 652 2037 $ 137,331 $ 3,788 The Company also has certain state net operating loss carryforwards totaling $134.6 2027 2037. may 382 may imitations on the Company’s ability to utilize the net operating loss carryforward. ASC 740 10, Accounting for Uncertainty in Income Taxes not” not not not not

Note N - Net Loss Per Share

Note N - Net Loss Per Share	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	N. Net Loss Per Share Under the two is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No no two two The following table summarizes the computation of basic and diluted net loss and net loss per share of the Company (in thousands, except share and pe r share amounts): Year ended December 31, 2017 2016 2015 Net loss - basic and diluted $ (43,386 ) $ (16,516 ) $ (54,664 ) Weighted average number of shares of common stock - basic and diluted 14,652,898 14,597,053 7,368,681 Net loss per share - basic and diluted $ (2.96 ) $ (1.13 ) $ (7.42 ) Diluted net loss per share is the same as basic net loss per share for all periods presented because the effects of potentially dilutive items were anti-dilutive given the Company ’s net loss. The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average number of shares of common stock outstanding because their effect is anti-dilutive: December 31, 2017 2016 2015 Warrants to purchase common stock 2,027,763 2,087,477 2,325,383 Awards under equity incentive plans 2,853,924 1,990,260 1,397,511 Deerfield Convertible Notes 1,751,410 1,751,296 1,991,219 2021 Notes 5,040,914 5,040,914 — Total securities excluded from the calculation of weighted average number of shares of common stock outstanding 11,674,011 10,869,947 5,714,113

Note O - Severance Expense

Note O - Severance Expense	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	O. Severance Expense On September 15, 2016, December 31, 2016. three $1.1 $1.9 December 31, 2016. As of December 31, 2017, no

Note P - Employee Benefit Plan

Note P - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	P. Employee Benefit Plan The Company has a 401 401 may 4% 401 $207,000, $213,000 $113,000 December 31, 2017, 2016 2015, The Company has a discretionary profit sharing plan (the “ Profit Sharing Plan”) that covers all employees. Employees become eligible participants in the Profit Sharing Plan once they have provided three no 2017, 2016 2015.

Note Q - Quarterly Results of O

Note Q - Quarterly Results of Operations (Unaudited)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Quarterly Financial Information [Text Block]	Q. Quarterly Results of Operations (unaudited) The following tables set forth unaudited quarterly statements of operations data for each of the quarters indicated. The financial statements for each of these quarters have been prepared on the same basis as the audited financial statements included herein and, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for the fair statement of the results of operations for these perio ds. You should read this information together with our financial statements and related notes included herein. These quarterly not Three-Months Ended Dec 31, Sep 30, Jun 30, Mar 31, Dec 31, Sep 30, Jun 30, Mar 31, 2017 2017 2017 2017 2016 2016 2016 2016 Revenue $ — $ — $ — $ — $ — $ — $ — $ — Operating expenses: Research and development 5,536 6,293 4,650 4,114 7,963 4,287 4,988 3,234 General and administrative 2,614 3,319 3,574 3,266 2,873 3,104 4,287 3,736 Severance expense — — — — — 3,010 — — Total operating expenses 8,150 9,612 8,224 7,380 10,836 10,401 9,275 6,970 Loss from operations (8,150 ) (9,612 ) (8,224 ) (7,380 ) (10,836 ) (10,401 ) (9,275 ) (6,970 ) Other (expense) income: Loss on extinguishment of debt — — — — — — — (4,740 ) Interest expense related to amortization of debt issuance costs and discount (390 ) (391 ) (390 ) (390 ) (391 ) (390 ) (393 ) (442 ) Interest expense on principal (1,444 ) (1,448 ) (1,443 ) (1,441 ) (1,445 ) (1,441 ) (1,475 ) (1,150 ) Fair value adjustment related to derivative and warrant liability (710 ) 1,312 3,523 (7,216 ) 2,723 (1,299 ) 20,763 10,278 Interest and other income, net 97 154 13 101 9 98 144 102 Total other (expense) income (2,447 ) (373 ) 1,703 (8,946 ) 896 (3,032 ) 19,039 4,048 (Loss) income before income taxes (10,597 ) (9,985 ) (6,521 ) (16,326 ) (9,940 ) (13,433 ) 9,764 (2,922 ) Income tax benefit (expense) 31 4 4 4 4 19 4 (12 ) Net (loss) income $ (10,566 ) $ (9,981 ) $ (6,517 ) $ (16,322 ) $ (9,936 ) $ (13,414 ) $ 9,768 $ (2,934 ) Net (loss) income per share: Basic $ (0.72 ) $ (0.68 ) $ (0.44 ) $ (1.11 ) $ (0.68 ) $ (0.92 ) $ 0.59 $ (0.20 ) Diluted $ (0.72 ) $ (0.68 ) $ (0.44 ) $ (1.11 ) $ (0.68 ) $ (0.92 ) $ (0.58 ) $ (0.20 )

Note R - Subsequent Events (Una

Note R - Subsequent Events (Unaudited)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	R. Subsequent Events On February 23, 2018, no 14

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Organization KemPharm, Inc. (the “Company”) is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy ("LAT") platform technology. The Company utilizes its proprietary LAT platform technology to generate improved prodrug versions of U.S. Food and Drug Administration (the "FDA") approved drugs in the high need areas of attention deficit hyperactivity disorder ("ADHD"), pain and other central nervous system ("CNS") disorders. The Company was formed and incorporated in Iowa on October 30, 2006 May 30, 2014.
Going Concern [Policy Text Block]	Going Concern The financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has experienced recurring losses from operations, stockholders' deficit and negative operating cash flows due to its ongoing research and development of its product and product candidates. The Company also has an accumulated deficit as of December 31, 2017. Management believes these conditions raise substantial doubt about the Company’s ability to continue as a going concern within the twelve Management intends to finance operating costs over the next twelve 3 $150.0 3 $20,000,000
Stockholders' Equity, Policy [Policy Text Block]	Initial Public Offering and Reverse Stock Split In April 2015, 1 7.5 250,000,000 10,000,000 $0.0001
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior year amounts have been reclassified to conform with current year presentation. During the second 2017, 2016 18, Statement of Cash Flows (Topic 230 2016 18” 2016 18 $1.1 December 31, 2016, not 2016 18. no not December 31, 2015.
Common Stock Sales Agreement (ATM Agreement), Policy [Policy Text Block]	Entry into ATM Agreement On October 3, 2016, may $50,000,000 3 October 17, 2016. 3 $20,000,000 Cowen may 415 1933, may three 3.0% The Company is not December 31, 2017, $0.2 As of March 28, 2018, 446,111 $2.9
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, includ ing those related to the useful lives of property and equipment, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed insured limits.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers any highly liquid investm ents with an original maturity of three
Marketable Securities, Policy [Policy Text Block]	Marketable Securities and Long-term Investments The Company maintains investment securities that are classified as trading securities. These securities are carried at fair value with unreali zed gains and losses included in other (expense) income on the statements of operations. The securities primarily consist of certificates of deposit, U.S. Treasury securities and U.S. government-sponsored agency securities.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three ten
Debt, Policy [Policy Text Block]	Debt Issuance Costs Debt issuance costs incurred in connection with financing arrangements are amortiz ed over the life of the respective financing arrangement using the effective interest method.
Collaborative Arrangement, Accounting Policy [Policy Text Block]	Supply Arrangements The Company enters into supply arrangements for the supply of components of its product and product candidates. These arrangements also may share of future revenue if related product or product candidates reach commercialization. Costs under these supply arrangements, if any, are expensed as incurred (Note H).
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not No December 31, 2017, 2016 2015.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three equent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three ● Level 1 —Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2 —Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3 —Unobservable inputs that are supported by little or no
Research and Development Expense, Policy [Policy Text Block]	Research and Development Major components of research and development costs include cash compensation, stock-based compensation, depreciation and amortization expense on research and development property and equipment, costs of preclinical studies, clin ical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Costs incurred in research and development are expensed as incurred. The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the statements of operations as the Company receives the related goods or services. The Company enters into contractual agreements with third pleted over an extended period of time. The Company records liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with the applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when the Company has not
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Costs Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative expenses on the statements of operations.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. Valuation allowances are recorded to reduce deferred tax assets to the amount the Company believes is more likely than not Uncertain tax positions are recognized only when the Company believes it is more likely than not t the tax position will be upheld on examination by the taxing authorities based on the merits of the position. The Company recognizes interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. The Company did not December 31, 2017 2016. The Company files income tax returns in the United States for federal and various state jurisdictions. With few exceptions, the Company is no 2013, 2013 may No
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers an d directors based on the estimated fair values of the awards as of the grant date. The Company records the value of the portion of the award that is ultimately expected to vest as expense over the requisite service period. The Company also accounts for equity instruments issued to non-employees using a fair value approach under Accounting Standards Codification ("ASC") subtopic 505 50.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Loss per Share of Common Stock The Company uses the two entitle the holders to participate in dividends and earnings of the Company. The two
Segment Reporting, Policy [Policy Text Block]	Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is ava ilable and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company views its operations and manages its business as a single operating and reporting segment. All assets of the Company were held in the United States as of December 31, 2017 2016.
New Accounting Pronouncements, Policy [Policy Text Block]	Application of New or Revised Accounting Standards —Adopted From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date . On April 5, 2012, JOBS Act”) into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may not In November 2015, 2015 17, Income Taxes: Balance Sheet Classification of Deferred Taxes (Topic 740 2015 17” December 15, 2016, 2015 17 not In March 2016, 2016 06, Derivatives and Hedging (Topic 815 2016 06” 2016 06 December 15, 2016, 2016 06 not In March 2016, 2016 09, Compensation–Stock Compensation (Topic 718 2016 09” 2016 09 December 15, 2016, 2016 09 not In November 2016, 2016 18, applies to all entities that have restricted cash or restricted cash equivalents and are required to present a statement of cash flows. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2017, The Company early adopted ASU 2016 18 second 2017. 2016 18
New Accounting Pronouncements, Not Yet Adopted, Policy [Policy Text Block]	Application of New or Revised Accounting Standards —Not In May 2014, 606, Revenue Recognition—Revenue from Contracts with Customers 606" 605, Revenue Recognition January 1, 2018. not not In January 2016, 2016 01, Financial Instruments Overall – Recognition and Measurement of Financial Assets and Liabilities (Topic 825 10 2016 01” 825 10. December 15, 2017, not 2016 01 In February 2016, 2016 02, Leases (Topic 842 2016 02” twelve 2016 02 December 15, 2018, 2016 02 . In August 2016, 2016 15, Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments (Topic 230 2016 15” eight 230. December 15, 2017, not currently expect ASU 2016 15 In May 2017, 2017 - 09, Compensation – Stock Compensation (Topic 718 ) – Scope of Modification Accounting ("ASU 2017 - 09" 718. This update applies to any entity that changes the terms or conditions of a stock-based payment award. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2017, not currently expect ASU 2017 - 09 to have a material effect on its financial statements and disclosures upon adoption. In July 2017, 2017 - 11, Earnings Per Share (Topic 260 ), Distinguishing Liabilities from Equity (Topic 480 ), Derivatives and Hedging (Topic 815 ) – I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception ("ASU 2017 - 11" 480 because of the existence of extensive pending content in the ASC as a result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. This update applies to all entities that issue financial instruments that include down round features and entities that present earnings per share in accordance with Topic 260. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2018, 2017 - 11 on its financial statements and disclosures.

Note C - Prepaid Expenses and26

Note C - Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, 2017 2016 Prepaid insurance $ 202 $ 333 Other receivables 76 58 Other prepaid expenses and current assets 1,384 98 Total prepaid expenses and other current assets $ 1,662 $ 489

Note D - Property and Equipme27

Note D - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2017 2016 Laboratory equipment $ 983 $ 842 Furniture and office equipment 655 733 Computers and hardware 292 231 Leasehold improvements 1,003 769 Total property and equipment 2,933 2,575 Less: accumulated depreciation and amortization (929 ) (605 ) Property and equipment, net $ 2,004 $ 1,970
Schedule of Capital Leased Assets [Table Text Block]	December 31, 2017 2016 Laboratory equipment $ 366 $ 271 Furniture and office equipment 541 537 Leasehold improvements 59 59 Total property and equipment financed under a capital lease agreement 966 867 Less: accumulated depreciation and amortization (150 ) (31 ) Property and equipment financed under a capital lease agreement, net $ 816 $ 836
Property, Plant and Equipment, Useful Life [Table Text Block]	Useful Life Asset Category (in years) Laboratory equipment 10 Furniture and office equipment 5 - 10 Computers and hardware 3 - 7 Leasehold improvements 9

Note E - Accounts Payable and28

Note E - Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, 2017 2016 Accrued interest $ 2,222 $ 2,222 Accrued banking fees 700 700 Accrued severance — 646 Accrued payroll 1,118 1,024 Accounts payable 2,177 469 Other accrued expenses 1,658 1,383 Total accounts payable and accrued expenses $ 7,875 $ 6,444

Note F - Debt Obligations (Tabl

Note F - Debt Obligations (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	Convertible Year Ending December 31, Notes 2018 $ 3,333 2019 3,333 2020 3,334 2021 86,250 Total minimum principal payments 96,250 Less: debt issuance costs and discount (3,519 ) Convertible notes, net $ 92,731

Note G - Commitments and Cont30

Note G - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]	Capital Operating Year Ending December 31, Leases Leases 2018 $ 242 $ 688 2019 231 604 2020 231 499 2021 151 449 2022 11 461 Thereafter — 1,376 Total minimum lease payments 866 $ 4,077 Less: amounts representing interest (115 ) Total minimum capital lease principal payments $ 751

Note I - Preferred Stock and 31

Note I - Preferred Stock and Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Temporary Equity [Table Text Block]	Shares of Series A Preferred Series B Preferred Series C Preferred Series D Preferred Series D-1 Preferred Total Balance as of January 1, 2015 9,704,215 6,220,000 18,557,408 7,255,425 — 41,737,048 Issuance of Series D-1 preferred stock — — — — 3,200,000 3,200,000 Exercise of Series D preferred warrants — — — 3,205 — 3,205 Effect of reverse stock split (8,410,377 ) (5,390,766 ) (16,083,286 ) (6,290,844 ) (2,784,416 ) (38,959,689 ) Less: Conversion of preferred stock into common stock upon IPO (1,293,838 ) (829,234 ) (2,474,122 ) (967,786 ) (415,584 ) (5,980,564 ) Balance as of December 31, 2015 — — — — — — Balance as of December 31, 2016 — — — — — — Balance as of December 31, 2017 — — — — — —

Note J - Common Stock and War32

Note J - Common Stock and Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block]	December 31, 2017 2016 Conversion of Deerfield Convertible Notes 1,751,410 1,751,296 Conversion of 2021 Notes 5,040,914 5,040,914 Outstanding awards under equity incentive plans 2,853,924 1,990,260 Outstanding common stock warrants 2,027,763 2,087,477 Possible future issuances under equity incentive plans 944,700 1,244,671 Total common shares reserved for future issuance 12,618,711 12,114,618
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Shares of Common Stock Balance as of January 1, 2015 2,381,041 Issuance of common stock in connection with the IPO 5,854,545 Conversion of preferred stock to common stock in connection with the IPO 5,980,564 Common stock warrants exercised 270,038 Common stock options exercised 4,766 Balance as of December 31, 2015 14,490,954 Common stock warrants exercised 141,095 Common stock options exercised 14,933 Balance as of December 31, 2016 14,646,982 Common stock warrants exercised 698 Common stock options exercised 9,750 Balance as of December 31, 2017 14,657,430

Note K - Stock-based Compensa33

Note K - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, 2017 2016 2015 Research and development $ 1,304 $ 1,051 $ 610 General and administrative 3,258 3,639 1,759 Severance expense — 1,910 — Total stock-based compensation expense $ 4,562 $ 6,600 $ 2,369
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	December 31, 2017 2016 2015 Risk-free interest rate 1.88% - 2.26% 1.29% - 1.50% 1.40% - 1.99% Expected term (in years) 5.12 - 7.00 5.50 - 6.26 4.33 - 6.25 Expected volatility 85.35% - 95.08% 77.38% - 94.78% 68.79% - 86.84% Expected dividend yield 0% 0% 0%
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Average Number of Weighted Average Remaining Contractual Aggregate Intrinsic Options Exercise Price Term (in years) Value Outstanding balance as of January 1, 2017 1,990,260 $ 13.64 8.27 $ 26,400 Granted 919,000 $ 3.59 Exercised (9,750 ) $ 0.75 Canceled or forfeited (38,920 ) $ 11.35 Expired (6,666 ) $ 4.65 Outsta nding balance as of December 31, 2017 2,853,924 $ 10.50 7.90 $ 471,539 Exercisable as of December 31, 2017 1,044,392 $ 12.38 6.78 $ 29,237 Vested and expected to vest as of December 31, 2017 2,760,447 $ 10.62 7.87 $ 440,178
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Average Weighted Average Number of Remaining Contractual Number of Remaining Contractual Exercise Price Shares Term (in years) Shares Term (in years) $2.75 to $5.00 1,055,244 8.69 76,244 3.75 $5.01 to $10.00 366,447 5.77 345,146 5.72 $10.01 to $15.00 471,833 7.94 189,291 7.73 $15.01 to $20.00 612,600 7.89 259,811 7.76 $20.01 to $22.12 347,800 7.68 173,900 7.68 2,853,924 7.90 1,044,392 6.78
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Unvested Shares December 31, Exercise Price 2017 2016 $2.75 to $5.00 979,000 99,000 $5.01 to $10.00 21,301 97,480 $10.01 to $15.00 282,542 378,500 $15.01 to $20.00 352,789 516,938 $20.01 to $22.12 173,900 260,850 Total number of unvested shares 1,809,532 1,352,768

Note L - Fair Value of Financ34

Note L - Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Quoted Prices in Balance as of Active Markets for Significant Other Significant December 31, Identical Assets Observable Inputs Unobservable Inputs 2017 (Level 1) (Level 2) (Level 3) Deerfield Warrant liability $ 5,115 $ — $ — $ 5,115 Embedded Warrant Put Option 365 — — 365 Fundamental change and make-whole interest provisions embedded in 2021 Notes 14 — — 14 Embedded Deerfield Note Put Option 2,215 — — 2.215 Total liabilities $ 7,709 $ — $ — $ 7,709 Trading securities: Certificates of deposit 5,616 5,616 — — U.S. Treasury securities 25,988 25,988 — — U.S. government-sponsored agency securities 3,004 — 3,004 — Total assets $ 34,608 $ 31,604 $ 3,004 $ — Quoted Prices in Balance as of Active Markets for Significant Other Significant December 31, Identical Assets Observable Inputs Unobservable Inputs 2016 (Level 1) (Level 2) (Level 3) Underwriter Warrant liability $ 16 $ — $ — $ 16 Deerfield Warrant liability 4,231 — — 4,231 Embedded Warrant Put Option 365 — — 365 Fundamental change and make-whole interest provisions embedded in 2021 Notes 6 6 Total liabilities $ 4,618 $ — $ — $ 4,618 Trading securities: Certificates of deposit 7,788 7,788 — — U.S. Treasury securities 37,066 37,066 — — U.S. government-sponsored agency securities 14,349 — 14,349 — Total assets $ 59,203 $ 44,854 $ 14,349 $ —
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	2017 2016 Balance as of beginning of period $ 4,618 $ 37,839 Exercise of warrants — (756 ) Adjustment to fair value 3,091 (32,465 ) Balance as of end of period $ 7,709 $ 4,618

Note M - Income Taxes (Tables)

Note M - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year ended December 31, 2017 2016 2015 Federal statutory rate 34.00 % 34.00 % 34.00 % Effect of: Change in valuation allowance 13.38 (69.31 ) (19.25 ) Return to provision and deferred true-up 2.18 (23.83 ) — Change in rate (49.06 ) (14.63 ) — State tax benefit (net of federal) 2.71 15.64 4.06 Warrant liability (2.42 ) 68.44 (15.28 ) State research and development credit 0.10 0.09 0.03 Federal research and development credit 1.50 5.65 0.84 Amortization (1.22 ) (3.15 ) — Conversion feature and put option on convertible notes — — (1.68 ) Stock-based compensation (1.03 ) (12.71 ) (1.28 ) Other (0.04 ) (0.10 ) (1.49 ) Federal income tax benefit (provision) effective rate 0.10 % 0.09 % (0.05 )%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2017 2016 2015 Deferred tax assets relating to: Net operating loss carryforwards $ 37,028 $ 44,984 $ 26,617 Research and development tax carryforward 3,788 3,166 2,254 Other deferred tax assets 2,409 715 232 Total gross deferred tax assets 43,225 48,865 29,103 Deferred tax liabilities relating to: Property and equipment 260 89 80 Total gross deferred tax liabilities 260 89 80 Deferred tax assets less liabilities 42,965 48,776 29,023 Valuation allowance (42,965 ) (48,776 ) (29,023 ) Net deferred tax asset (liability) $ — $ — $ —
Summary of Operating Loss Carryforwards [Table Text Block]	Net Operating Research Year Incurred Loss Carryforwards Activities Credit Expiration 2007 $ 454 $ 30 2027 2008 1,178 65 2028 2009 3,060 176 2029 2010 3,423 149 2030 2011 9,929 176 2031 2012 — 170 2032 2013 4,353 133 2033 2014 16,265 894 2034 2015 24,126 598 2035 2016 40,715 745 2036 2017 33,828 652 2037 $ 137,331 $ 3,788

Note N - Net Loss Per Share (Ta

Note N - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year ended December 31, 2017 2016 2015 Net loss - basic and diluted $ (43,386 ) $ (16,516 ) $ (54,664 ) Weighted average number of shares of common stock - basic and diluted 14,652,898 14,597,053 7,368,681 Net loss per share - basic and diluted $ (2.96 ) $ (1.13 ) $ (7.42 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2017 2016 2015 Warrants to purchase common stock 2,027,763 2,087,477 2,325,383 Awards under equity incentive plans 2,853,924 1,990,260 1,397,511 Deerfield Convertible Notes 1,751,410 1,751,296 1,991,219 2021 Notes 5,040,914 5,040,914 — Total securities excluded from the calculation of weighted average number of shares of common stock outstanding 11,674,011 10,869,947 5,714,113

Note Q - Quarterly Results of37

Note Q - Quarterly Results of Operations (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Quarterly Financial Information [Table Text Block]	Three-Months Ended Dec 31, Sep 30, Jun 30, Mar 31, Dec 31, Sep 30, Jun 30, Mar 31, 2017 2017 2017 2017 2016 2016 2016 2016 Revenue $ — $ — $ — $ — $ — $ — $ — $ — Operating expenses: Research and development 5,536 6,293 4,650 4,114 7,963 4,287 4,988 3,234 General and administrative 2,614 3,319 3,574 3,266 2,873 3,104 4,287 3,736 Severance expense — — — — — 3,010 — — Total operating expenses 8,150 9,612 8,224 7,380 10,836 10,401 9,275 6,970 Loss from operations (8,150 ) (9,612 ) (8,224 ) (7,380 ) (10,836 ) (10,401 ) (9,275 ) (6,970 ) Other (expense) income: Loss on extinguishment of debt — — — — — — — (4,740 ) Interest expense related to amortization of debt issuance costs and discount (390 ) (391 ) (390 ) (390 ) (391 ) (390 ) (393 ) (442 ) Interest expense on principal (1,444 ) (1,448 ) (1,443 ) (1,441 ) (1,445 ) (1,441 ) (1,475 ) (1,150 ) Fair value adjustment related to derivative and warrant liability (710 ) 1,312 3,523 (7,216 ) 2,723 (1,299 ) 20,763 10,278 Interest and other income, net 97 154 13 101 9 98 144 102 Total other (expense) income (2,447 ) (373 ) 1,703 (8,946 ) 896 (3,032 ) 19,039 4,048 (Loss) income before income taxes (10,597 ) (9,985 ) (6,521 ) (16,326 ) (9,940 ) (13,433 ) 9,764 (2,922 ) Income tax benefit (expense) 31 4 4 4 4 19 4 (12 ) Net (loss) income $ (10,566 ) $ (9,981 ) $ (6,517 ) $ (16,322 ) $ (9,936 ) $ (13,414 ) $ 9,768 $ (2,934 ) Net (loss) income per share: Basic $ (0.72 ) $ (0.68 ) $ (0.44 ) $ (1.11 ) $ (0.68 ) $ (0.92 ) $ 0.59 $ (0.20 ) Diluted $ (0.72 ) $ (0.68 ) $ (0.44 ) $ (1.11 ) $ (0.68 ) $ (0.92 ) $ (0.58 ) $ (0.20 )

Note A - Description of Busin38

Note A - Description of Business and Basis of Presentation (Details Textual)	1 Months Ended	12 Months Ended			18 Months Ended
	Apr. 30, 2015$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Mar. 22, 2018USD ($)shares	Oct. 17, 2016USD ($)	Oct. 03, 2016USD ($)
Sale of Securities, Value, Available to Issue		$ 150,000,000
Sale of Stock, Value, Available to Issue		$ 20,000,000
Common Stock, Shares Authorized | shares	250,000,000	250,000,000	250,000,000
Preferred Stock, Shares Authorized | shares	10,000,000	10,000,000	10,000,000
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Net Cash Provided by (Used in) Investing Activities		$ 27,412,000	$ (45,847,000)	$ (19,137,000)
Restricted Cash				0
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect		$ (5,891,000)	$ (14,456,000)	$ 22,063,000
Other Noncurrent Assets [Member]
Deferred Offering Costs		$ 200,000
Cowen and Company, LLC [Member]
Sale of Stock, Authorized Offering Price						$ 20,000,000
Sale of Stock, Commission Fee						3.00%
Cowen and Company, LLC [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues | shares					446,111
Proceeds from Issuance of Common Stock					$ 2,900,000
Cowen and Company, LLC [Member] | Maximum [Member]
Sale of Stock, Authorized Offering Price							$ 50,000,000
Accounting Standards Update 2016-18 [Member] | Restatement Adjustment [Member]
Net Cash Provided by (Used in) Investing Activities			1,100,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect			$ 1,100,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	7.5

Note B - Summary of Significa39

Note B - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Asset Impairment Charges	$ 0	$ 0	$ 0
Unrecognized Tax Benefits	$ 0	$ 0
Number of Operating Segments	1
Number of Reportable Segments	1
Earliest Tax Year [Member]
Open Tax Year	2,013
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years

Note C - Prepaid Expenses and40

Note C - Prepaid Expenses and Other Current Assets - Components of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Prepaid insurance	$ 202	$ 333
Other receivables	76	58
Other prepaid expenses and current assets	1,384	98
Total prepaid expenses and other current assets	$ 1,662	$ 489

Note D - Property and Equipme41

Note D - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Depreciation, Depletion and Amortization	$ 336,000	$ 175,000	$ 84,000

Note D - Property and Equipme42

Note D - Property and Equipment - Components of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property and equipment, gross	$ 2,933	$ 2,575
Less: accumulated depreciation and amortization	(929)	(605)
Property and equipment, net	2,004	1,970
Laboratory Equipment [Member]
Property and equipment, gross	983	842
Furniture and Fixtures [Member]
Property and equipment, gross	655	733
Computer and Hardware [Member]
Property and equipment, gross	292	231
Leasehold Improvements [Member]
Property and equipment, gross	$ 1,003	$ 769

Note D - Property and Equipme43

Note D - Property and Equipment - Assets Under Capital Leases Included in Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Capital leased assets, gross	$ 966	$ 867
Less: accumulated depreciation and amortization	(150)	(31)
Property and equipment financed under a capital lease agreement, net	816	836
Laboratory Equipment [Member]
Capital leased assets, gross	366	271
Furniture and Fixtures [Member]
Capital leased assets, gross	541	537
Leasehold Improvements [Member]
Capital leased assets, gross	$ 59	$ 59

Note D - Property and Equipme44

Note D - Property and Equipment - Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2017
Minimum [Member]
Property and equipment, useful lives (Year)	3 years
Maximum [Member]
Property and equipment, useful lives (Year)	10 years
Laboratory Equipment [Member]
Property and equipment, useful lives (Year)	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property and equipment, useful lives (Year)	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property and equipment, useful lives (Year)	10 years
Computer and Hardware [Member] | Minimum [Member]
Property and equipment, useful lives (Year)	3 years
Computer and Hardware [Member] | Maximum [Member]
Property and equipment, useful lives (Year)	7 years
Leasehold Improvements [Member]
Property and equipment, useful lives (Year)	9 years

Note E - Accounts Payable and45

Note E - Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued interest	$ 2,222	$ 2,222
Accrued banking fees	700	700
Accrued severance		646
Accrued payroll	1,118	1,024
Accounts payable	2,177	469
Other accrued expenses	1,658	1,383
Total accounts payable and accrued expenses	$ 7,875	$ 6,444

Note F - Debt Obligations (Deta

Note F - Debt Obligations (Details Textual) - USD ($)	Feb. 09, 2016	Jun. 02, 2014	Jan. 31, 2018	Dec. 31, 2017	Jun. 30, 2016	Apr. 30, 2015	Dec. 31, 2013
Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						15,499,324	1,079,453
2021 Notes [Member]
Debt Instrument, Convertible, Conversion Price	$ 17.11
Debt Instrument, Face Amount	$ 86,300,000
Debt Instrument, Interest Rate, Stated Percentage	5.50%
Proceeds from Debt, Net of Issuance Costs	$ 82,800,000
Repayments of Long-term Debt	18,600,000
Debt Instrument, Sinking Fund Payment	$ 0
Debt Conversion, Converted Instrument, Shares Issued	58.4454
Debt Conversion, Original Debt, Amount	$ 1,000
Debt Instrument Repurchase Price Equal to Percentage of Principal Amount	100.00%
Deerfield Facility Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 60,000,000
Line of Credit Facility, Interest Rate at Period End		9.75%
Debt Covenant, Debt Financing Restriction		$ 750,000
Deerfield Facility Agreement [Member] | IPO [Member]
Reclassification of Common Stock Shares		256,410
Deerfield Facility Agreement [Member] | Deerfield Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.78
Deerfield Facility Agreement [Member] | Deerfield Warrant [Member] | IPO [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,923,077
Deerfield Facility Agreement [Member] | Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		14,423,076
Own-share Lending Arrangement, Shares, Issued		1,923,077
Mandatorily Redeemable Preferred Stock, Fair Value Disclosure		$ 1,500,000
Deerfield Facility Agreement [Member] | Term Notes [Member]
Proceeds from Secured Notes Payable		15,000,000
Deerfield Facility Agreement [Member] | Deerfield Convertible Notes [Member]
Proceeds from Secured Notes Payable		$ 10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.85
Debt Instrument, Convertible, Conversion Price		$ 5.85
Third Line of Credit Agreement [Member] | City National Bank of Florida [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 1,100,000
Line of Credit Facility, Remaining Borrowing Capacity				$ 400,000
Long-term Line of Credit				$ 0
Third Line of Credit Agreement [Member] | City National Bank of Florida [Member] | Prime Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage				3.36%
Debt Instrument, Basis Spread on Variable Rate				2.00%
Third Line of Credit Agreement [Member] | City National Bank of Florida [Member] | Subsequent Event [Member]
Line of Credit Facility, Expiration Period			2 years

Note F - Debt Obligations - Fut

Note F - Debt Obligations - Future Minimum Payments (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,018	$ 3,333
2,019	3,333
2,020	3,334
2,021	86,250
Total minimum principal payments	96,250
Less: debt issuance costs and discount	(3,519)
Convertible notes, net	$ 92,731

Note G - Commitments and Cont48

Note G - Commitments and Contingencies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Loss Contingency Accrual	$ 0	$ 0
Operating and Capital Leases, Rent Expense, Net	$ 600	$ 600	$ 300
Capital Lease One [Member]
Capital Lease, Interest Rate	7.19%
Capital Lease Two [Member]
Capital Lease, Interest Rate	8.05%
Iowa [Member]
Lessee, Operating Lease, Renewal Term	1 year
Florida [Member]
Lessee, Operating Lease, Renewal Term	5 years
Number of Units Leased	2
Lessee Leasing Arrangements, Operating Leases, Number of Lease Renewals	2
North Carolina [Member]
Lessee, Operating Lease, Renewal Term	3 years

Note G - Commitment and Conting

Note G - Commitment and Contingencies - Future Minimum Lease Payments Under Capital Leases and Non-cancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,018	$ 242
2,018	688
2,019	231
2,019	604
2,020	231
2,020	499
2,021	151
2,021	449
2,022	11
2,022	461
Thereafter
Thereafter	1,376
Total minimum lease payments	866
Total minimum lease payments	4,077
Less: amounts representing interest	(115)
Total minimum capital lease principal payments	$ 751

Note H - Supply Arrangement (De

Note H - Supply Arrangement (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Number of Manufacturing Arrangements	1
Supply Arrangement Expense	$ 0	$ 0	$ 0
Supply Arrangement, Automatic Renewal Period	2 years
Supply Arrangement, Period of Prior Notice	1 year

Note I - Preferred Stock and 51

Note I - Preferred Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Jun. 02, 2014	Apr. 30, 2015	Feb. 28, 2015	Dec. 31, 2015	Dec. 31, 2013	Dec. 31, 2017	Dec. 31, 2016
Preferred Stock, Shares Authorized		10,000,000				10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.0001				$ 0.0001	$ 0.0001
Preferred Stock, Shares Outstanding						0	0
Conversion of Preferred Stock to Common Stock Upon Initial Public Offering Shares				5,980,564
2013 Warrants [Member]
Class of Warrant or Right Issued					1,079,453
Deerfield Warrant [Member]
Class of Warrant or Right Issued	14,423,076
Convertible Notes Payable [Member]
Debt Instrument, Face Amount					$ 3.8
Series D-1 Redeemable Convertible Preferred Stock [Member]
Conversion of Preferred Stock to Common Stock Upon Initial Public Offering Shares				415,584
Series D-1 Redeemable Convertible Preferred Stock [Member] | Cowen KP Investment LLC [Member]
Temporary Equity Shares Issuance			3,200,000
Sale of Stock, Price Per Share			$ 1.25
Proceeds from Issuance of Redeemable Convertible Preferred Stock			$ 4
Conversion of Preferred Stock to Common Stock Upon Initial Public Offering Shares			415,584
Series D Redeemable Convertible Preferred Stock [Member]
Conversion of Preferred Stock to Common Stock Upon Initial Public Offering Shares				967,786
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		15,499,324			1,079,453
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,066,543			143,466
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5.85
Common Stock [Member] | Deerfield Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,923,077
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.85
Common Stock [Member] | IPO [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities		5,980,564		5,980,564

Note I - Preferred Stock and 52

Note I - Preferred Stock and Warrants - Summary of Redeemable Convertible Preferred Stock Activity (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014
Balance (in shares)
Less: Conversion of preferred stock into common stock upon IPO (in shares)	(5,980,564)
Scenario, Previously Reported [Member]
Balance (in shares)				41,737,048
Temporary Equity Shares Issuance	3,200,000
Exercise of Series D preferred warrants (in shares)	3,205
Restatement Adjustment [Member]
Effect of reverse stock split (in shares)	(38,959,689)
Series A Redeemable Convertible Preferred Stock [Member]
Balance (in shares)
Less: Conversion of preferred stock into common stock upon IPO (in shares)	(1,293,838)
Series A Redeemable Convertible Preferred Stock [Member] | Scenario, Previously Reported [Member]
Balance (in shares)				9,704,215
Temporary Equity Shares Issuance
Exercise of Series D preferred warrants (in shares)
Series A Redeemable Convertible Preferred Stock [Member] | Restatement Adjustment [Member]
Effect of reverse stock split (in shares)	(8,410,377)
Series B Redeemable Convertible Preferred Stock [Member]
Balance (in shares)
Less: Conversion of preferred stock into common stock upon IPO (in shares)	(829,234)
Series B Redeemable Convertible Preferred Stock [Member] | Scenario, Previously Reported [Member]
Balance (in shares)				6,220,000
Temporary Equity Shares Issuance
Exercise of Series D preferred warrants (in shares)
Series B Redeemable Convertible Preferred Stock [Member] | Restatement Adjustment [Member]
Effect of reverse stock split (in shares)	(5,390,766)
Series C Redeemable Convertible Preferred Stock [Member]
Balance (in shares)
Less: Conversion of preferred stock into common stock upon IPO (in shares)	(2,474,122)
Series C Redeemable Convertible Preferred Stock [Member] | Scenario, Previously Reported [Member]
Balance (in shares)				18,557,408
Temporary Equity Shares Issuance
Exercise of Series D preferred warrants (in shares)
Series C Redeemable Convertible Preferred Stock [Member] | Restatement Adjustment [Member]
Effect of reverse stock split (in shares)	(16,083,286)
Series D Redeemable Convertible Preferred Stock [Member]
Balance (in shares)
Less: Conversion of preferred stock into common stock upon IPO (in shares)	(967,786)
Series D Redeemable Convertible Preferred Stock [Member] | Scenario, Previously Reported [Member]
Balance (in shares)				7,255,425
Temporary Equity Shares Issuance
Exercise of Series D preferred warrants (in shares)	3,205
Series D Redeemable Convertible Preferred Stock [Member] | Restatement Adjustment [Member]
Effect of reverse stock split (in shares)	(6,290,844)
Series D-1 Redeemable Convertible Preferred Stock [Member]
Balance (in shares)
Less: Conversion of preferred stock into common stock upon IPO (in shares)	(415,584)
Series D-1 Redeemable Convertible Preferred Stock [Member] | Scenario, Previously Reported [Member]
Balance (in shares)
Temporary Equity Shares Issuance	3,200,000
Exercise of Series D preferred warrants (in shares)
Series D-1 Redeemable Convertible Preferred Stock [Member] | Restatement Adjustment [Member]
Effect of reverse stock split (in shares)	(2,784,416)

Note J - Common Stock and War53

Note J - Common Stock and Warrants (Details Textual) - USD ($)	12 Months Ended			18 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 22, 2018	Apr. 30, 2015	Dec. 31, 2012
Common Stock, Shares Authorized	250,000,000	250,000,000			250,000,000
Common Stock, Shares, Issued	14,657,430	14,646,982
Common Stock Issued During Period from Warrants Exercised	698	141,095	270,038
Subsequent Event [Member] | Cowen and Company, LLC [Member]
Stock Issued During Period, Shares, New Issues				446,111
Proceeds from Issuance of Common Stock				$ 2,900,000
Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						595,920

Note J - Common Stock and War54

Note J - Common Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) - shares	Dec. 31, 2017	Dec. 31, 2016
Common shares reserved for future issuance (in shares)	12,618,711	12,114,618
Warrant [Member]
Common shares reserved for future issuance (in shares)	2,027,763	2,087,477
Stock Compensation Plan [Member]
Common shares reserved for future issuance (in shares)	2,853,924	1,990,260
Possible Future Issuances Under Equity Incentive Plans [Member]
Common shares reserved for future issuance (in shares)	944,700	1,244,671
2021 Notes [Member]
Common shares reserved for future issuance (in shares)	5,040,914	5,040,914
Convertible Notes Payable [Member]
Common shares reserved for future issuance (in shares)	1,751,410	1,751,296

Note J - Common Stock and War55

Note J - Common Stock and Warrants - Common Stock Activity (Details) - shares	1 Months Ended	12 Months Ended
	Apr. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Balance (in shares)		14,646,982	14,490,954	2,381,041
Common stock warrants exercised (in shares)		698	141,095	270,038
Common stock options exercised (in shares)		9,750	14,933	4,766
Balance (in shares)		14,657,430	14,646,982	14,490,954
Common Stock [Member] | IPO [Member]
Issuance of common stock in connection with the IPO (in shares)				5,854,545
Conversion of preferred stock to common stock in connection with the IPO (in shares)	5,980,564			5,980,564

Note K - Stock-based Compensa56

Note K - Stock-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Increase in Common Stock Reserved for Issuance	586,297
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	9,750	14,933	4,766
Stock Issued During Period, Value, Stock Options Exercised	$ 7,000	$ 71,000	$ 28,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 32,000	$ 169,000	$ 54,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	$ 2.77	$ 9.25	$ 10.63
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 4,100,000	$ 5,400,000	$ 1,100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 8,500,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 21 days
Allocated Share-based Compensation Expense	$ 4,562,000	$ 6,600,000	$ 2,369,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		13,333	163,998
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	1,304,000	$ 1,051,000	$ 610,000
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	3,258,000	3,639,000	1,759,000
Performance Shares [Member]
Allocated Share-based Compensation Expense	$ 0
Performance Shares [Member] | Research and Development Expense [Member]
Allocated Share-based Compensation Expense		$ 44,000	200,000
Performance Shares [Member] | General and Administrative Expense [Member]
Allocated Share-based Compensation Expense			$ 700,000
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,432,183
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding	4.00%

Note K - Stock-based Compensa57

Note K - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock based compensation expense	$ 4,562	$ 6,600	$ 2,369
Research and Development Expense [Member]
Stock based compensation expense	1,304	1,051	610
General and Administrative Expense [Member]
Stock based compensation expense	3,258	3,639	1,759
Severance Expense [Member]
Stock based compensation expense		$ 1,910

Note K - Stock-based Compensa58

Note K - Stock-based Compensation - Black-Scholes Option-pricing Model (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Expected dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Risk-free interest rate	1.88%	1.29%	1.40%
Expected term (in years) (Year)	5 years 43 days	5 years 182 days	4 years 120 days
Expected volatility	85.35%	77.38%	68.79%
Maximum [Member]
Risk-free interest rate	2.26%	1.50%	1.99%
Expected term (in years) (Year)	7 years	6 years 94 days	6 years 91 days
Expected volatility	95.08%	94.78%	86.84%

Note K - Stock-based Compensa59

Note K - Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Outstanding, number of options (in shares)	1,990,260
Outstanding, weighted average exercise price (in dollars per share)	$ 13.64
Outstanding, weighted average remaining contractual term (Year)	7 years 328 days	8 years 98 days
Outstanding, aggregate intrinsic value	$ 471,539	$ 26,400
Granted, number of options (in shares)	919,000
Granted, weighted average exercise price (in dollars per share)	$ 3.59
Exercised, number of options (in shares)	(9,750)	(14,933)	(4,766)
Exercised, weighted average exercise price (in dollars per share)	$ 0.75
Canceled or forfeited, number of options (in shares)	(38,920)
Canceled or forfeited, weighted average exercise price (in dollars per share)	$ 11.35
Expired, number of options (in shares)	(6,666)
Expired, weighted average exercise price (in dollars per share)	$ 4.65
Outstanding, number of options (in shares)	2,853,924	1,990,260
Outstanding, weighted average exercise price (in dollars per share)	$ 10.50	$ 13.64
Exercisable, number of options (in shares)	1,044,392
Exercisable, weighted average exercise price (in dollars per share)	$ 12.38
Exercisable, weighted average remaining contractual term (Year)	6 years 284 days
Exercisable, aggregate intrinsic value	$ 29,237
Vested and expected to vest, number of options (in shares)	2,760,447
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 10.62
Vested and expected to vest, weighted average remaining contractual term (Year)	7 years 317 days
Vested and expected to vest, aggregate intrinsic value	$ 440,178

Note K - Stock-based Compensa60

Note K - Stock-based Compensation - Information Regarding Currently Outstanding and Exercisable Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Options outstanding, number of shares (in shares)	2,853,924	1,990,260
Outstanding, weighted average remaining contractual term (Year)	7 years 328 days	8 years 98 days
Exercisable, number of options (in shares)	1,044,392
Exercisable, weighted average remaining contractual term (Year)	6 years 284 days
Exercise Price Range One [Member]
Lower range (in dollars per share)	$ 2.75
Upper range (in dollars per share)	$ 5
Options outstanding, number of shares (in shares)	1,055,244
Outstanding, weighted average remaining contractual term (Year)	8 years 251 days
Exercisable, number of options (in shares)	76,244
Exercisable, weighted average remaining contractual term (Year)	3 years 273 days
Exercise Price Range Two [Member]
Lower range (in dollars per share)	$ 5.01
Upper range (in dollars per share)	$ 10
Options outstanding, number of shares (in shares)	366,447
Outstanding, weighted average remaining contractual term (Year)	5 years 281 days
Exercisable, number of options (in shares)	345,146
Exercisable, weighted average remaining contractual term (Year)	5 years 262 days
Exercise Price Range Three [Member]
Lower range (in dollars per share)	$ 10.01
Upper range (in dollars per share)	$ 15
Options outstanding, number of shares (in shares)	471,833
Outstanding, weighted average remaining contractual term (Year)	7 years 343 days
Exercisable, number of options (in shares)	189,291
Exercisable, weighted average remaining contractual term (Year)	7 years 266 days
Exercise Price Range Four [Member]
Lower range (in dollars per share)	$ 15.01
Upper range (in dollars per share)	$ 20
Options outstanding, number of shares (in shares)	612,600
Outstanding, weighted average remaining contractual term (Year)	7 years 324 days
Exercisable, number of options (in shares)	259,811
Exercisable, weighted average remaining contractual term (Year)	7 years 277 days
Exercise Price Range Five [Member]
Lower range (in dollars per share)	$ 20.01
Upper range (in dollars per share)	$ 22.12
Options outstanding, number of shares (in shares)	347,800
Outstanding, weighted average remaining contractual term (Year)	7 years 248 days
Exercisable, number of options (in shares)	173,900
Exercisable, weighted average remaining contractual term (Year)	7 years 248 days

Note K - Stock-based Compensa61

Note K - Stock-based Compensation - Nonvested Stock Option Awards (Details) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Number of unvested shares (in shares)	1,809,532	1,352,768
Exercise Price Range One [Member]
Number of unvested shares (in shares)	979,000	99,000
Exercise Price Range One [Member] | Minimum [Member]
Exercise price (in dollars per share)	$ 2.75
Exercise Price Range One [Member] | Maximum [Member]
Exercise price (in dollars per share)	$ 5
Exercise Price Range Two [Member]
Number of unvested shares (in shares)	21,301	97,480
Exercise Price Range Two [Member] | Minimum [Member]
Exercise price (in dollars per share)	$ 5.01
Exercise Price Range Two [Member] | Maximum [Member]
Exercise price (in dollars per share)	$ 10
Exercise Price Range Three [Member]
Number of unvested shares (in shares)	282,542	378,500
Exercise Price Range Three [Member] | Minimum [Member]
Exercise price (in dollars per share)	$ 10.01
Exercise Price Range Three [Member] | Maximum [Member]
Exercise price (in dollars per share)	$ 15
Exercise Price Range Four [Member]
Number of unvested shares (in shares)	352,789	516,938
Exercise Price Range Four [Member] | Minimum [Member]
Exercise price (in dollars per share)	$ 15.01
Exercise Price Range Four [Member] | Maximum [Member]
Exercise price (in dollars per share)	$ 20
Exercise Price Range Five [Member]
Number of unvested shares (in shares)	173,900	260,850
Exercise Price Range Five [Member] | Minimum [Member]
Exercise price (in dollars per share)	$ 20.01
Exercise Price Range Five [Member] | Maximum [Member]
Exercise price (in dollars per share)	$ 22.12

Note L - Fair Value of Financ62

Note L - Fair Value of Financial Instruments (Details Textual) - Fair Value, Inputs, Level 3 [Member] - Deerfield Facility Agreement [Member] - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Deerfield Convertible Notes [Member]
Long-term Debt, Fair Value	$ 11	$ 10.2
Term Notes [Member]
Long-term Debt, Fair Value	$ 51.9	$ 46.3

Note L - Fair Value of Financ63

Note L - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Financial liabilities measured at fair value on recurring basis	$ 7,709,000	$ 4,618,000
Financial assets measured at fair value on recurring basis	34,608,000	59,203,000
Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis	5,616,000	7,788,000
US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis	25,988,000	37,066,000
US Government Corporations and Agencies Securities [Member]
Financial assets measured at fair value on recurring basis	3,004,000	14,349,000
Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Financial assets measured at fair value on recurring basis	31,604,000	44,854,000
Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis	5,616,000	7,788,000
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis	25,988,000	37,066,000
Fair Value, Inputs, Level 1 [Member] | US Government Corporations and Agencies Securities [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Financial assets measured at fair value on recurring basis	3,004,000	14,349,000
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member] | US Government Corporations and Agencies Securities [Member]
Financial assets measured at fair value on recurring basis	3,004,000	14,349,000
Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	7,709,000	4,618,000
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] | US Government Corporations and Agencies Securities [Member]
Financial assets measured at fair value on recurring basis
Deerfield Warrant Liability [Member]
Financial liabilities measured at fair value on recurring basis	5,115,000	4,231,000
Deerfield Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Deerfield Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Deerfield Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	5,115,000	4,231,000
Underwriter Warrant Liability [Member]
Financial liabilities measured at fair value on recurring basis		16,000
Underwriter Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Underwriter Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Underwriter Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis		16,000
Embedded Put Option [Member]
Financial liabilities measured at fair value on recurring basis	365,000	365,000
Embedded Put Option [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Put Option [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Put Option [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	365,000	365,000
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member]
Financial liabilities measured at fair value on recurring basis	14,000	6,000
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	14,000	$ 6,000
Embedded Deerfield Note Put Option [Member]
Financial liabilities measured at fair value on recurring basis	2,215,000
Embedded Deerfield Note Put Option [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Deerfield Note Put Option [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Deerfield Note Put Option [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	$ 2,215

Note L - Fair Value of Financ64

Note L - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Balance as of beginning of period	$ 4,618	$ 37,839
Exercise of warrants		(756)
Adjustment to fair value	3,091	(32,465)
Balance as of end of period	$ 7,709	$ 4,618

Note M - Income Taxes (Details

Note M - Income Taxes (Details Textual) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
State and Local Income Tax Expense (Benefit), Continuing Operations									$ (43,000)	$ (15,000)	$ (15,000)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (10,597,000)	$ (9,985,000)	$ (6,521,000)	$ (16,326,000)	$ (9,940,000)	$ (13,433,000)	$ 9,764,000	$ (2,922,000)	(43,429,000)	$ (16,531,000)	$ (54,638,000)
Operating Loss Carryforwards	137,331,000								137,331,000
Increase (Decrease) in Deferred Tax Assets									(21.30)
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 134,600,000								$ 134,600,000
Operating Loss Carryforwards, Expiration, Beginning Year									2,027
Operating Loss Carryforwards, Expiration, Ending Year									2,037

Note M - Income Taxes - Schedul

Note M - Income Taxes - Schedule of Reconciliation of Difference Between Benefit for Income Taxes and Income Taxes at Statutory U.S. Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Federal statutory rate	34.00%	34.00%	34.00%
Change in valuation allowance	13.38%	(69.31%)	(19.25%)
Return to provision and deferred true-up	2.18%	(23.83%)
Change in rate	(49.06%)	(14.63%)
State tax benefit (net of federal)	2.71%	15.64%	4.06%
Warrant liability	(2.42%)	68.44%	(15.28%)
Amortization	(1.22%)	(3.15%)
Conversion feature and put option on convertible notes			(1.68%)
Stock-based compensation	(1.03%)	(12.71%)	(1.28%)
Other	(0.04%)	(0.10%)	(1.49%)
Federal income tax benefit (provision) effective rate	0.10%	0.09%	(0.05%)
State and Local Jurisdiction [Member]
Research and development credit	0.10%	0.09%	0.03%
Domestic Tax Authority [Member]
Research and development credit	1.50%	5.65%	0.84%

Note M - Income Taxes - Compone

Note M - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net operating loss carryforwards	$ 37,028	$ 44,984	$ 26,617
Research and development tax carryforward	3,788	3,166	2,254
Other deferred tax assets	2,409	715	232
Total gross deferred tax assets	43,225	48,865	29,103
Property and equipment	260	89	80
Total gross deferred tax liabilities	260	89	80
Deferred tax assets less liabilities	42,965	48,776	29,023
Valuation allowance	(42,965)	(48,776)	(29,023)
Net deferred tax asset (liability)

Note M - Income Taxes - Federal

Note M - Income Taxes - Federal Net Operating Loss Carryforward and Research Activities Credit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net Operating Loss Carryforwards	$ 137,331
Research Activities Tax Credit	$ 3,788	$ 3,166	$ 2,254
Expiration
Tax Year 2007 [Member]
Net Operating Loss Carryforwards	$ 454
Research Activities Tax Credit	$ 30
Expiration	2,027
Tax Year 2008 [Member]
Net Operating Loss Carryforwards	$ 1,178
Research Activities Tax Credit	$ 65
Expiration	2,028
Tax Year 2009 [Member]
Net Operating Loss Carryforwards	$ 3,060
Research Activities Tax Credit	$ 176
Expiration	2,029
Tax Year 2010 [Member]
Net Operating Loss Carryforwards	$ 3,423
Research Activities Tax Credit	$ 149
Expiration	2,030
Tax Year 2011 [Member]
Net Operating Loss Carryforwards	$ 9,929
Research Activities Tax Credit	$ 176
Expiration	2,031
Tax Year 2012 [Member]
Net Operating Loss Carryforwards
Research Activities Tax Credit	$ 170
Expiration	2,032
Tax Year 2013 [Member]
Net Operating Loss Carryforwards	$ 4,353
Research Activities Tax Credit	$ 133
Expiration	2,033
Tax Year 2014 [Member]
Net Operating Loss Carryforwards	$ 16,265
Research Activities Tax Credit	$ 894
Expiration	2,034
Tax Year 2015 [Member]
Net Operating Loss Carryforwards	$ 24,126
Research Activities Tax Credit	$ 598
Expiration	2,035
Tax Year 2016 [Member]
Net Operating Loss Carryforwards	$ 40,715
Research Activities Tax Credit	$ 745
Expiration	2,036
Tax Year 2017 [Member]
Net Operating Loss Carryforwards	$ 33,828
Research Activities Tax Credit	$ 652
Expiration	2,037

Note N - Net Loss Per Share - S

Note N - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss and Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net loss - basic and diluted	$ (10,566)	$ (9,981)	$ (6,517)	$ (16,322)	$ (9,936)	$ (13,414)	$ 9,768	$ (2,934)	$ (43,386)	$ (16,516)	$ (54,664)
Weighted average number of shares of common stock - basic and diluted (in shares)									14,652,898	14,597,053	7,368,681
Net loss per share - basic and diluted (in dollars per share)									$ (2.96)	$ (1.13)	$ (7.42)

Note N - Net Loss Per Share - A

Note N - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive securities (in shares)	11,674,011	10,869,947	5,714,113
Warrants to Purchase Common Stock [Member]
Antidilutive securities (in shares)	2,027,763	2,087,477	2,325,383
Stock Compensation Plan [Member]
Antidilutive securities (in shares)	2,853,924	1,990,260	1,397,511
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	1,751,410	1,751,296	1,991,219
2021 Notes [Member]
Antidilutive securities (in shares)	5,040,914	5,040,914

Note O - Severance Expense (Det

Note O - Severance Expense (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Restructuring and Related Cost, Number of Positions Eliminated		3
Allocated Share-based Compensation Expense	$ 4,562	$ 6,600	$ 2,369
Severance Expense [Member]
Allocated Share-based Compensation Expense		1,910
Employee Severance [Member] | Accounts Payable and Accrued Liabilities [Member]
Restructuring Reserve	$ 0
Employee Severance [Member] | Severance Expense [Member]
Restructuring Charges		1,100
Allocated Share-based Compensation Expense		$ 1,900

Note P - Employee Benefit Plan

Note P - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Retirement Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 207,000	$ 213,000	$ 113,000
Profit Sharing Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0	$ 0
Defined Contribution Plan, Requisite Service Period	3 years

Note Q - Quarterly Results of73

Note Q - Quarterly Results of Operations (Unaudited) - Schedule of Quarterly Operating Results (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue
Operating expenses:
Research and development	5,536	6,293	4,650	4,114	7,963	4,287	4,988	3,234	20,593	20,472	13,931
General and administrative	2,614	3,319	3,574	3,266	2,873	3,104	4,287	3,736	12,773	14,000	8,883
Severance expense						3,010				3,010
Total operating expenses	8,150	9,612	8,224	7,380	10,836	10,401	9,275	6,970	33,366	37,482	22,814
Loss from operations	(8,150)	(9,612)	(8,224)	(7,380)	(10,836)	(10,401)	(9,275)	(6,970)	(33,366)	(37,482)	(22,814)
Other (expense) income:
Loss on extinguishment of debt								(4,740)		(4,740)
Interest expense related to amortization of debt issuance costs and discount	(390)	(391)	(390)	(390)	(391)	(390)	(393)	(442)	(1,561)	(1,616)	(1,909)
Interest expense on principal	(1,444)	(1,448)	(1,443)	(1,441)	(1,445)	(1,441)	(1,475)	(1,150)	(5,776)	(5,511)	(2,671)
Fair value adjustment related to derivative and warrant liability	(710)	1,312	3,523	(7,216)	2,723	(1,299)	20,763	10,278	(3,091)	32,465	(27,276)
Interest and other income, net	97	154	13	101	9	98	144	102	365	353	32
Total other (expense) income	(2,447)	(373)	1,703	(8,946)	896	(3,032)	19,039	4,048	(10,063)	20,951	(31,824)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(10,597)	(9,985)	(6,521)	(16,326)	(9,940)	(13,433)	9,764	(2,922)	(43,429)	(16,531)	(54,638)
Income tax benefit (expense)	31	4	4	4	4	19	4	(12)	43	15	(26)
Net loss - basic and diluted	$ (10,566)	$ (9,981)	$ (6,517)	$ (16,322)	$ (9,936)	$ (13,414)	$ 9,768	$ (2,934)	$ (43,386)	$ (16,516)	$ (54,664)
Net loss per share:
Basic (in dollars per share)	$ (0.72)	$ (0.68)	$ (0.44)	$ (1.11)	$ (0.68)	$ (0.92)	$ 0.59	$ (0.20)
Diluted (in dollars per share)	$ (0.72)	$ (0.68)	$ (0.44)	$ (1.11)	$ (0.68)	$ (0.92)	$ (0.58)	$ (0.20)